Compare BEAM & KLIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEAM | KLIC |
|---|---|---|
| Founded | 2017 | 1951 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2020 | N/A |
| Metric | BEAM | KLIC |
|---|---|---|
| Price | $26.68 | $46.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $48.09 | $46.67 |
| AVG Volume (30 Days) | ★ 2.0M | 766.4K |
| Earning Date | 11-04-2025 | 02-03-2026 |
| Dividend Yield | N/A | ★ 1.71% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | $55,701,000.00 | ★ $654,081,000.00 |
| Revenue This Year | N/A | $20.77 |
| Revenue Next Year | $26.52 | $8.23 |
| P/E Ratio | ★ N/A | $11,819.78 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.53 | $26.63 |
| 52 Week High | $35.25 | $52.08 |
| Indicator | BEAM | KLIC |
|---|---|---|
| Relative Strength Index (RSI) | 55.81 | 58.15 |
| Support Level | $25.86 | $47.50 |
| Resistance Level | $28.10 | $49.69 |
| Average True Range (ATR) | 1.56 | 1.65 |
| MACD | 0.17 | 0.02 |
| Stochastic Oscillator | 57.39 | 45.14 |
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Kulicke & Soffa Industries Inc. is a United States-based company that is principally engaged in designing, manufacturing, and selling capital equipment and expendable tools that are used for assembling semiconductor devices. The company has four reportable segments, which include Ball Bonding Equipment, Wedge Bonding Equipment, Advanced Solutions, and Aftermarket Products and Services. Its Ball Bonding Equipment segment which generates the majority of the revenue for the company includes results of the company from the design, development, manufacture and sale of ball bonding equipment and wafer level bonding equipment. The majority of its customers are located in the Asia-pacific region.